The general mood among these heavyweight investors is divided, with 44% leaning bullish and 33% bearish. Among these notable options, 5 are puts, totaling $256,004, and 4 are calls, amounting to ...

Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that its Board of Directors (the “Board”) has approved an amendment to its previously disclosed limited duration ...

Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to ...

Innate Pharma continues its slow rollout of promising clinical candidates, with 2025 set for key milestones. Read more about ...

Ultimately, Chimerix’s board went with Jazz’s offer due to its cash payable nature and the recent downward trend in biopharma ...

French food ingredient maker Roquette reported a sharp drop in core profit in 2024 on Friday, citing weaker sales in its main ingredients market, but good performance in its pharmaceutical activities ...

The growing preference for plant-based and naturally derived pharmaceuticals is fueling the expansion of the Natural APIs ...

Researchers at Indiana University and Wuhan University in China have unveiled a groundbreaking chemical process that could ...

The ALS research landscape is evolving rapidly, with groundbreaking advancements shaping the future of therapeutic ...

Lynn Stockwell, the new Chief Executive Officer and Chairman of the Board of Directors of Bright Green Corporation, is also the CEO, Chair and sponsors and manages other NASDAQ listed corporations ...

HHS, a $1.6 trillion agency, includes the National Institutes of Health (NIH), the Centers for Disease Control and Prevention ...

There’s been no shortage of either in recent weeks. Plunging valuations across the biotech sector were thrust into the ...